Effect of Including Cancer Mortality on the Cost-Effectiveness of Aspirin for Primary Prevention in Men
Recent data suggest that aspirin may be effective for reducing cancer mortality.
To examine whether including a cancer mortality-reducing effect influences which men would benefit from aspirin for primary prevention.
We modified our existing Markov model that examines the effects of aspirin among middle-aged men with no previous history of cardiovascular disease or diabetes. For our base case scenario of 45-year-old men, we examined costs and life-years for men taking aspirin for 10 years compared with men who were not taking aspirin over those 10 years; after 10 years, we equalized treatment and followed the cohort until death. We compared our results depending on whether or not we included a 22 % relative reduction in cancer mortality, based on a recent meta-analysis. We discounted costs and benefits at 3 % and employed a third party payer perspective.
Cost per quality-adjusted life year (QALY) gained.
When no effect on cancer mortality was included, aspirin had a cost per QALY gained of $22,492 at 5 % 10-year coronary heart disease (CHD) risk; at 2.5 % risk or below, no treatment was favored. When we included a reduction in cancer mortality, aspirin became cost-effective for men at 2.5 % risk as well (cost per QALY, $43,342). Results were somewhat sensitive to utility of taking aspirin daily; risk of death after myocardial infarction; and effects of aspirin on stroke, myocardial infarction, and sudden death. However, aspirin remained cost-saving or cost-effective (< $50,000 per QALY) in probabilistic analyses (59 % with no cancer effect included; 96 % with cancer effect) for men at 5 % risk.
Including an effect of aspirin on cancer mortality influences the threshold for prescribing aspirin for primary prevention in men. If such an effect is real, many middle-aged men at low cardiovascular risk would become candidates for regular aspirin use.
KEY WORDSaspirin cancer mortality coronary heart disease guideline-based intervention primary prevention
- 2.Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: asex-specific meta-analysis of randomized controlled trials. JAMA. 2006;295(3):306–13. Erratum in: JAMA. 2006 May 3;295(17):2002. PubMed PMID:16418466.PubMedCrossRefGoogle Scholar
- 12.Greving JP, Buskens E, Koffijberg H, Algra A. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk. Circulation. 2008;117(22):2875–83. Epub 2008 May 27. PubMed PMID: 18506010.PubMedCrossRefGoogle Scholar
- 19.Kung HC, Hoyert DL, Xu JQ, Murphy SL. Deaths: Final Data for 2005. National Vital Statistics Reports; vol 56 no 10. Hyattsville, MD: National Center for Health Statistics; 2008.Google Scholar
- 20.Surveillance, Epidemiology, and End Results Program. SEER*Stat Database: Mortality - All COD, Aggregated With State, Total U.S. (1969-2007), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2009. Available at: www.seer.cancer.gov. Accessed on September 8, 2011.
- 23.Rothwell PM, Price JF, Fowkes FG, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012;379(9826):1602–12. Epub 2012 Mar 21. Review. PubMed PMID: 22440946.PubMedCrossRefGoogle Scholar
- 28.U.S. Department of Labor, U.S. Bureau of Labor Statistics, US city average, not seasonally adjusted medical care. http://data.bls.gov/PDQ/outside.jsp?survey=cu. Accessed February 2012.
- 29.Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 Patients. Am J Med. 2012 Jun 27.[Epub ahead of print] PubMed PMID: 22748400.Google Scholar
- 32.www.Walgreens.com, accessed 9Sep11.
- 33.Ingenix, Inc. The Essential RBRVS (2012): A comprehensive listing of RBRVS values for CPT and HCPCS Codes. St. Anthony Publishing, 2012.Google Scholar
- 34.HCUPnet. Healthcare Cost and Utilization Project (HCUP). 2009. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/HCUPnet/ Accessed 7Mar2012.
- 38.Leibson CL, Hu T, Brown RD, Hass SL, O’Fallon WM, Whisnant JP. Utilization of acute care services in the year before and after first stroke: A population-based study. Neurology. 1996;46(3):1–13.Google Scholar